LungPlasma
Therapy selection for Non-Small Cell Lung Cancer (NSCLC)
ApprovedCommercial
Key Facts
Indication
Therapy selection for Non-Small Cell Lung Cancer (NSCLC)
Phase
Approved
Status
Commercial
Company
About Burning Rock Biotech
Burning Rock Biotech is a publicly-traded, commercial-stage diagnostics company specializing in precision oncology. Its core mission is to transform cancer treatment through early detection and personalized therapy selection using advanced genomic profiling. The company has established a significant commercial footprint in China with its portfolio of NGS-based in-vitro diagnostic (IVD) products and laboratory-developed tests (LDTs), while actively developing its multi-cancer early detection (MCED) pipeline. Its strategic direction involves expanding its product portfolio, pursuing regulatory approvals, and exploring international markets.
View full company profile